Literature DB >> 14672505

Nitric oxide synthase expression and enzymatic activity in human brain tumors.

H Broholm1, I Rubin, A Kruse, O Braendstrup, K Schmidt, E B Skriver, M Lauritzen.   

Abstract

Nitric oxide (NO) is synthesized by NO synthases (NOS), existing in 3 isoforms. NO influences a great variety of vital functions including vascular tone and neurotransmission. Under conditions of excessive formation, NO emerges as an important mediator of neurotoxicity in a variety of disorders of the central nervous system (CNS). Inhibitors of NOS are available that may modify the activity of all isoforms, which may be of clinical relevance. The expression of the 3 NOS isoforms nNOS, iNOS and eNOS and NOS enzymatic activity was examined in 40 patients with primary CNS tumors (gliomas WHO grades I - IV and meningeomas WHO grades I - III) and in 13 patients with metastases from adenocarcinomas or malignant melanomas. A polyclonal antibody directed against nNOS and monoclonal antibodies directed against iNOS and eNOS were used for immunohistochemical staining. NOS enzymatic activity, measured by labeled arginine to citrulline conversion, was assessed in tissue specimens obtained from the same tumors. NOS data were compared with clinical variables and the degree of edema as judged from MR scanning. nNOS expression was increased in tumor cells of glial neoplasms and most pronounced in high-grade tumors, WHO grades III and IV, and in the carcinoma and melanoma metastases. Low-grade gliomas, WHO grades I and II and meningeomas expressed no or only little nNOS. iNOS was only expressed in a few tumors. eNOS was expressed sporadically in the tumor cells while the expression was increased in vascular endothelial cells in both the tumor itself and the peritumoral area of glial neoplasms, and in metastases. eNOS expression was sporadic in endothelial cells of meningeomas. NOS enzymatic activities were heterogeneous among tumor types (0 - 13.8 pmol/min/mg of protein) without correlation to the NOS expression found by immunohistochemical techniques. Likewise, NOS activity and expression was not correlated to the clinical scores or brain edema. In conclusion, nNOS expression may be a putative useful indicator of brain tumor differentiation and malignancy. The enhanced expression of eNOS in vascular endothelial cells of glial neoplasms and metastases raises the possibility that NO production in tumor endothelial cells may contribute to tumor blood flow regulation and possibly brain edema.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14672505

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  23 in total

Review 1.  Nitric oxide and cancer therapy: the emperor has NO clothes.

Authors:  Jason R Hickok; Douglas D Thomas
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 2.  NOS Expression and NO Function in Glioma and Implications for Patient Therapies.

Authors:  Anh N Tran; Nathaniel H Boyd; Kiera Walker; Anita B Hjelmeland
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

Review 3.  Long non-coding RNAs in nervous system function and disease.

Authors:  Irfan A Qureshi; John S Mattick; Mark F Mehler
Journal:  Brain Res       Date:  2010-04-07       Impact factor: 3.252

4.  Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by epimuqubilin A via IKK/IκB/NF-κB pathways in lipopolysaccharide-stimulated RAW 264.7 cells.

Authors:  Eun-Jung Park; Sarot Cheenpracha; Leng Chee Chang; John M Pezzuto
Journal:  Phytochem Lett       Date:  2011-12-01       Impact factor: 1.679

5.  Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells.

Authors:  Nikki Charles; Tatsuya Ozawa; Massimo Squatrito; Anne-Marie Bleau; Cameron W Brennan; Dolores Hambardzumyan; Eric C Holland
Journal:  Cell Stem Cell       Date:  2010-02-05       Impact factor: 24.633

Review 6.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

7.  Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells.

Authors:  Fernando Francisco Borges Resende; Simoneide Souza Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Oncol Lett       Date:  2018-02-01       Impact factor: 2.967

Review 8.  Nitric oxide and cancer: a review.

Authors:  Sheetal Korde Choudhari; Minal Chaudhary; Sachin Bagde; Amol R Gadbail; Vaishali Joshi
Journal:  World J Surg Oncol       Date:  2013-05-30       Impact factor: 2.754

9.  Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide.

Authors:  Nicholas A Pullen; Helen L Fillmore
Journal:  J Neurooncol       Date:  2009-07-21       Impact factor: 4.130

Review 10.  Regulatory mechanisms of long noncoding RNAs in vertebrate central nervous system development and function.

Authors:  J L Knauss; T Sun
Journal:  Neuroscience       Date:  2013-01-18       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.